share_log

榮昌生物：海外監管公告 - 關於最近五年被證券監管部門和證券交易所採取監管措施或處罰情況的公告

REMEGEN: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Apr 2 00:22
Summary by Moomoo AI
榮昌生物製藥（煙台）股份有限公司（「榮昌生物」）於2024年4月2日發布公告，就公司最近五年內是否存在被證券監管部門和上海證券交易所處罰或采取監管措施的情況進行了自查。自查結果顯示，在過去五年中，榮昌生物未曾受到證券監管部門的處罰。然而，公司於2023年4月23日收到上海證券交易所的口頭警示，原因是公司未及時履行信息披露義務，涉及一筆2900萬元的政府補助，該筆款項占公司最近一期經審計淨利潤的10.5%。對此，榮昌生物及時任董事會秘書温庆凯表示重視，並已採取措施加強內部管控和規範運作，以確保信息披露的及時性和準確性。公告強調，除了上述口頭警示外，公司在最近五年內沒有其他被監管措施的情況。
榮昌生物製藥（煙台）股份有限公司（「榮昌生物」）於2024年4月2日發布公告，就公司最近五年內是否存在被證券監管部門和上海證券交易所處罰或采取監管措施的情況進行了自查。自查結果顯示，在過去五年中，榮昌生物未曾受到證券監管部門的處罰。然而，公司於2023年4月23日收到上海證券交易所的口頭警示，原因是公司未及時履行信息披露義務，涉及一筆2900萬元的政府補助，該筆款項占公司最近一期經審計淨利潤的10.5%。對此，榮昌生物及時任董事會秘書温庆凯表示重視，並已採取措施加強內部管控和規範運作，以確保信息披露的及時性和準確性。公告強調，除了上述口頭警示外，公司在最近五年內沒有其他被監管措施的情況。
Wing Cheong Biopharmaceuticals (Yantai) Co., Ltd. (“Wing Cheong Biologics”) issued a notice on April 2, 2024 that the Company conducted a self-examination of the existence of sanctions or regulatory measures imposed by the Securities Regulatory Department and the Shanghai Stock Exchange in the last five years. The results showed that in the past five years, Rung Cheong Bio has not been penalized by the securities regulator. However, the company received a verbal warning from the Shanghai Stock Exchange on April 23, 2023, due to the company's failure to timely fulfill its disclosure obligations involving a government subsidy of $2900 million, which represented 10.5% of the company's most recent audited net profit. In this regard, Wing Cheong Biological and Current Board Secretary, Wen King-kai, expressed the importance and measures have been taken to strengthen internal controls and regulatory operations to ensure the timeliness and accuracy of information disclosure. The announcement highlights that the company has had no other regulatory measures in the last five years in addition to the aforementioned verbal warnings.
Wing Cheong Biopharmaceuticals (Yantai) Co., Ltd. (“Wing Cheong Biologics”) issued a notice on April 2, 2024 that the Company conducted a self-examination of the existence of sanctions or regulatory measures imposed by the Securities Regulatory Department and the Shanghai Stock Exchange in the last five years. The results showed that in the past five years, Rung Cheong Bio has not been penalized by the securities regulator. However, the company received a verbal warning from the Shanghai Stock Exchange on April 23, 2023, due to the company's failure to timely fulfill its disclosure obligations involving a government subsidy of $2900 million, which represented 10.5% of the company's most recent audited net profit. In this regard, Wing Cheong Biological and Current Board Secretary, Wen King-kai, expressed the importance and measures have been taken to strengthen internal controls and regulatory operations to ensure the timeliness and accuracy of information disclosure. The announcement highlights that the company has had no other regulatory measures in the last five years in addition to the aforementioned verbal warnings.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more